Skip to main content
Caplight Logo









ARCALIS, Inc.

ARCALIS, Inc.

Private
JapanHealthcare & Life Scienceshttp://arcalis.co.jp/

Last Round

Strategic

Nov 14, 2024

Total Funding Raised

$274.11M

Company Overview

ARCALIS, Inc. is a biotechnology company that operates as a contract development and manufacturing organization (CDMO) specializing in mRNA vaccines and therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain, Drug Discovery, Smart Manufacturing, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

CDMOmRNA manufacturingcontract manufacturingmRNA vaccinesfill and finishprocess developmentchemistry manufacturing and controlCMCdrug substance manufacturingbiotech manufacturinganalytical testingmRNA therapeuticsbiopharma outsourcinggene therapy productionbiotech supply chain

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ARCALIS, Inc. Comparables

Compare ARCALIS, Inc. with similar companies based on industry and business-model similarity.

ARCALIS, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RiboPro
84%
Vernal Biosciences
82%
Anemocyte
80%

ARCALIS, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicNov 14, 2024
DebtJan 31, 2024
GrantOct 4, 2023
DebtOct 31, 2022

ARCALIS, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors increased 128% MoM, reaching 5.8K.

  • Oct 29, 2024

    Monthly visitors increased 188% MoM, reaching 7.5K.

ARCALIS, Inc. Filings

Explore SEC and related filing metadata, where available.

ARCALIS, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ARCALIS, Inc.'s valuation, stock price, and market status.

Is ARCALIS, Inc. a public or private company?

ARCALIS, Inc. is a private company.

What is the current stock price of ARCALIS, Inc.?

ARCALIS, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is ARCALIS, Inc. worth (valuation)?

Valuation information for ARCALIS, Inc. is not publicly available.

Can I buy ARCALIS, Inc. stock?

ARCALIS, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ARCALIS, Inc.'s last funding round?

ARCALIS, Inc.'s most recent funding round was Strategic on November 14, 2024.

Who are the main investors in ARCALIS, Inc.?

Key investors in ARCALIS, Inc. include Sumitomo Mitsui Trust Bank, Joyo Bank, Ltd., Ministry of Economy, Trade and Industry, Aozora Bank, Sumitomo Mitsui Banking Corporation.

Will ARCALIS, Inc. IPO soon?

No public IPO plans have been announced for ARCALIS, Inc..

How can I track ARCALIS, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ARCALIS, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersJapan
Employee Range31
Year Founded2021
Last FundingNov 14, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?